Evotec SE (EVO) FCF Payout Ratio Growth (1y) (2010 - 2026)
Evotec SE (EVO) FCF Payout Ratio Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.85 Bn | 39.19 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.40 Bn | 29.73 Bn | 1.05 Bn | -14.68% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -49.97% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | -49.30% |
| 7 | Neurocrine Biosciences | 15.42 Bn | 15.03 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Evotec SE | 689.00 Mn | 688.53 Mn | - | 7,589.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,589.89% |
| Sep 30, 2025 | 1,278.11% |
| Jun 30, 2025 | -102.80% |
| Mar 31, 2025 | 61.13% |
| Sep 30, 2024 | -76.71% |
| Jun 30, 2024 | 3,996.00% |
| Mar 31, 2024 | -454.96% |
| Sep 30, 2023 | -39.37% |
| Jun 30, 2023 | 96.09% |
| Mar 31, 2023 | -256.79% |
| Sep 30, 2022 | -86.61% |
| Jun 30, 2022 | -72.32% |
| Mar 31, 2022 | -99.94% |
| Jun 30, 2010 | -529.00% |
| Mar 31, 2010 | 118.08% |